Virtu KCG Holdings’s Altamira Therapeutics Ltd CYTO Stock Holding History

Virtu KCG Holdings’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$101K	Buy	+2	New	+$113K	﹤0.01%	2413
2017 Q1	–	Hold	0	–	-$22K	–	3891
2016 Q4	–	Hold	0	–	–	–	3225
2016 Q3	–	Hold	0	–	–	–	2800
2016 Q2	–	Hold	0	–	-$46K	–	3423
2016 Q1	–	Hold	0	–	–	–	2479
2015 Q4	–	Hold	0	–	–	–	3165

Other funds holding CYTO

SMV

Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Virtu KCG Holdings's CYTO Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Altamira Therapeutics Ltd (CYTO) in Q2 2017: 2 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #2413 among its holdings.

9 funds tracked by Wall St. Rank hold CYTO as of Q2 2017.

Virtu KCG Holdings held 2 shares of Altamira Therapeutics Ltd worth $101K as of Q2 2017.
Altamira Therapeutics Ltd was a new Virtu KCG Holdings position in Q2 2017.
Altamira Therapeutics Ltd made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2413 holding.
9 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.